SNDX News and Press, Syndax Pharmaceuticals Inc. From 04/08/21

Syndax Pharmaceuticals (SNDX) is up ~4.4% in after-hours on the announcement of Orphan Drug Designation granted by the FDA for its anti-CSF-1R monoclonal antibody Axatilimab for the treatment of idiopathic pulmonary fibrosis (“IPF”).Given for drug candidates ...

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis PR Newswire WALTHAM, Mass. , April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stag...

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease PR Newswire WALTHAM, Mass. , March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a cli...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2021 – Cancer research and development are a major part of the biotechnology industry, and there is always room for improvement and growth. Recently, biotech company Perimete...

Syndax Pharmaceutials (SNDX) has filed a mixed shelf offering of $75M.The filing does not necessarily indicate that a sale has begun, or will occur in the future.The company's two lead candidates are SNDX-6352 (axatilimab) in phase 2 for chronic graft-versus-host disease and SNDX-5613 in...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2020 Results Conference Call March 08, 2021 04:30 PM ET Company Participants Maghan Meyers - Argot Partners Dr. Briggs Morrison - Chief Executive Officer Daphne Karydas - Chief Financial Officer Michael Metzger - President, Chief Operating Officer Dr. Mi...

Syndax Pharmaceuticals (SNDX): Q4 GAAP EPS of -$0.44 beats by $0.03.Cash, cash equivalents and short-term investments of $293.1M and 51.4M shares and share equivalents issued and outstanding.Shares -1.2% AH.Press Release For further details see: Syndax Pharmaceuticals EPS beats by ...

Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AG...

Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021 PR Newswire WALTHAM, Mass. , March 1, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SND...